ReviewFrontiers in microbiology2026
Advances in the application of recombinant herpesvirus-vectored vaccines in animal disease control.
Review in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recombinant herpesvirus vectors have emerged as highly potent platforms for next-generation vaccine development, distinguished by their genomic capacity and their unique ability to elicit durable, long-lasting immunity through persistent latent infections. In this review, we trace the evolutionary trajectory of herpesvirus vector engineering-transitioning from traditional homologous recombination to advanced bacterial artificial chromosome (BAC) systems and precise, scarless CRISPR/Cas9 gene editing. We comprehensively evaluate the rational design of classical animal herpesvirus vectors, including pseudorabies virus (PRV), herpesvirus of turkeys (HVT), and feline herpesvirus type 1 (FHV-1). Specifically, we highlight their distinct advantages in molecular attenuation, the optimization of non-essential insertion loci, and the application of tissue-specific promoters for multiplexed antigen presentation. Furthermore, we discuss the strategic deployment of multivalent herpesvirus vaccines within the "One Health" framework, emphasizing their critical role in simplifying immunization protocols and interrupting the transmission chains of zoonotic diseases. Finally, we address the prevailing translational bottlenecks, including scalable manufacturing challenges and stringent regulatory frameworks regarding environmental release, providing perspectives on how continuous biotechnological innovations will empower herpesvirus vectors to serve as formidable prophylactic tools against emerging and re-emerging infectious diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.